Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page’s revision label was updated from v3.6.2 to v3.6.3, indicating a small site update with no visible changes to the study details or eligibility criteria.SummaryDifference0.1%

- Check28 days agoChange DetectedThe revision tag on the page was updated from v3.6.0 to v3.6.2, signaling an internal update to the site's backend or documentation rather than any change to the clinical trial details presented.SummaryDifference0.1%

- Check42 days agoChange DetectedThe study record's contact/sponsor details were updated to separate the investigator's name from the institution, and additional help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), accompanied by a revision tag (v3.6.0).SummaryDifference2%

- Check49 days agoChange DetectedThe page revision tag was updated from v3.5.4 to v3.5.5, indicating a new version of the page content. The change updates the page metadata but does not alter the trial details.SummaryDifference0.1%

- Check71 days agoChange DetectedThe revision tag on the page has been updated from v3.5.3 to v3.5.4, indicating a new page version. This is a metadata/version update and does not modify the study content or data presented.SummaryDifference0.1%

- Check85 days agoChange DetectedThe page now displays the updated site revision, v3.5.3, replacing the previous v3.5.2; this indicates a software deployment rather than a change to trial information.SummaryDifference0.1%

Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.